Jiangsu Hengrui Pharmaceuticals Co.,Ltd Share Price
Equities
600276
CNE0000014W7
Pharmaceuticals
OTC Markets Traded|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 47.08 CNY | +0.97% |
|
-6.20% | -20.97% |
| 06-06 | Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data At Ada 2026 | CI |
| 05-29 | Hengrui Pharma Secures China Registration for Gout Drug; Shares Up 3% | MT |
| Capitalization | 312B 46.02B 39.85B 36.57B 34.4B 64.08B 4,385B 65.08B 435B 169B 2,121B 173B 169B 7,375B | P/E ratio 2026 * |
33.5x | P/E ratio 2027 * | 28x |
|---|---|---|---|---|---|
| Enterprise value | 267B 39.37B 34.09B 31.28B 29.43B 54.81B 3,751B 55.67B 372B 145B 1,814B 148B 145B 6,309B | EV / Sales 2026 * |
7.41x | EV / Sales 2027 * | 6.25x |
| Free-Float |
51.65% | Yield 2026 * |
0.58% | Yield 2027 * | 0.65% |
| 1 day | +0.97% | ||
| 1 week | -6.20% | ||
| Current month | -6.20% | ||
| 1 month | -12.21% | ||
| 3 months | -15.26% | ||
| 6 months | -23.60% | ||
| Current year | -20.97% |
| 1 week | 46.51 |  | 51.2 |
| 1 month | 46.51 | | 58.87 |
| Current year | 46.51 | | 65.83 |
| 1 year | 46.51 | | 74.04 |
| 3 years | 35.51 | | 74.04 |
| 5 years | 27 | | 75.46 |
| 10 years | 14.01 | | 97.39 |
| Manager | Title | Age | Since |
|---|---|---|---|
Jian Jun Liu
DFI | Director of Finance/CFO | 49 | 18/11/2021 |
Ji Feng
PSD | President | 55 | 01/04/2025 |
Yu Xu
CMP | Compliance Officer | 34 | 31/05/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
Jie Ping Sun
BRD | Director/Board Member | 56 | 15/01/2020 |
Hong Bin Dai
BRD | Director/Board Member | 49 | 15/01/2020 |
Piao Yang Sun
CHM | Chairman | 67 | 07/07/2021 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 03-24 | Other | Director | 49,000 | 0.0190% | ||
| 03-24 | Other | Chairperson | 75,000 | 0.0290% | ||
| 11-07 | Other | Chairperson | 120,000 | 0.0019% |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.97% | -6.20% | -12.49% | +1.66% | 46.02B | |
| +0.55% | +2.39% | +46.96% | +155.36% | 1,009B | |
| +2.02% | +3.30% | +50.15% | +47.16% | 560B | |
| +1.02% | +4.37% | +19.70% | +67.78% | 401B | |
| +0.77% | -0.67% | +21.96% | +11.96% | 328B | |
| +2.24% | +0.41% | +28.53% | +17.12% | 288B | |
| +1.85% | +0.14% | +21.53% | +30.34% | 272B | |
| +4.43% | -3.11% | -42.11% | -49.56% | 194B | |
| +1.15% | +3.80% | +20.41% | +58.02% | 189B | |
| -0.02% | -3.92% | +14.85% | +69.50% | 160B | |
| Average | +1.50% | +0.60% | +16.95% | +40.93% | 344.75B | |
| Weighted average by Cap. | +1.34% | +1.86% | +29.62% | +69.62% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 36.01B 5.32B 4.6B 4.22B 3.97B 7.4B 507B 7.52B 50.21B 19.54B 245B 19.96B 19.52B 852B | 41.63B 6.15B 5.32B 4.88B 4.59B 8.56B 586B 8.69B 58.04B 22.59B 283B 23.08B 22.57B 985B |
| Net income | 9.29B 1.37B 1.19B 1.09B 1.03B 1.91B 131B 1.94B 12.96B 5.04B 63.23B 5.15B 5.04B 220B | 11.02B 1.63B 1.41B 1.29B 1.22B 2.26B 155B 2.3B 15.36B 5.98B 74.95B 6.11B 5.97B 261B |
| Net Debt | -45.06B -6.65B -5.76B -5.29B -4.97B -9.26B -634B -9.41B -62.83B -24.45B -307B -24.98B -24.43B -1,066B | -51.68B -7.63B -6.61B -6.06B -5.7B -10.62B -727B -10.79B -72.06B -28.04B -352B -28.65B -28.02B -1,223B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 05/06/26 | 47.08 ¥ | +0.97% | 93,026,390 |
| 04/06/26 | 46.63 ¥ | -1.21% | 63,924,880 |
| 03/06/26 | 47.20 ¥ | -2.48% | 81,536,420 |
| 02/06/26 | 48.40 ¥ | -1.57% | 61,144,310 |
| 01/06/26 | 49.17 ¥ | -2.03% | 94,665,290 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 600276 Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition